Noema Pharma is a technology company.
Noema Pharma is a clinical-stage biotech pioneering a portfolio of disease transforming therapeutics for CNS-mediated conditions.
Noema Pharma has raised $260.0M across 2 funding rounds.
Noema Pharma has raised $260.0M in total across 2 funding rounds.
Noema Pharma has raised $260.0M in total across 2 funding rounds.
Noema Pharma's investors include EQT Life Sciences, Forbion, Karista, Pfizer Venture Investments, Seroba Life Sciences, Soffinova Partners.
Noema Pharma is a clinical-stage biotechnology company, not a technology company in the software or hardware sense, focused on developing novel therapeutics for central nervous system (CNS)-mediated conditions, including orphan diseases and prevalent disorders of the brain and nervous system.[1][2][3][6] It targets debilitating symptoms in conditions like trigeminal neuralgia, Tourette syndrome, vasomotor symptoms of menopause (hot flashes), and tuberous sclerosis complex, with a pipeline including NOE-101 (mGluR5 inhibitor), NOE-105 (PDE10A inhibitor/gemlapodect), and NOE-115 (triple reuptake inhibitor).[3][4][8] The company serves patients, families, caregivers, and healthcare professionals by advancing phase 2/3, 2b, and 2a clinical studies, aiming to transform lives beyond symptom control through disease-modifying therapies.[1][2][6] Growth momentum includes recent milestones like dosing first patients in a Phase 2b study for NOE-105 in Tourette syndrome, meeting primary and key secondary endpoints in a Phase 2a study, extending Series B financing to CHF 130 million ($147 million), and appointing key executives such as CFO Michael Samar and EVP R&D Volker Knappertz.[4]
Noema Pharma, headquartered in Basel, Switzerland, emerged as a Swiss-based biotech licensing mid-clinical-stage therapeutic products from Roche, leveraging their established safety profiles to target orphan neurological disorders with imbalanced neuronal networks.[4][3] While specific founding year and founders are not detailed in available sources, the company's leadership team brings extensive experience from global biotech and pharmaceutical firms, with a proven track record in developing and commercializing CNS treatments.[6] Early traction stems from strategic in-licensing and partnerships with investors like Sofinnova Partners, Forbion, Glide Healthcare, Invus, Roche, BioMed Partners, and Polaris Partners, enabling rapid pipeline advancement into multiple Phase 2 trials.[2][3][4][5] Pivotal moments include recent clinical progress and financing extensions, positioning Noema as a focused player in CNS therapeutics.[4]
Noema Pharma rides the wave of advancing CNS therapeutics, addressing unmet needs in orphan neurological disorders and prevalent conditions like menopause symptoms amid growing demand for non-opioid, targeted brain therapies.[1][3][8] Timing aligns with post-pandemic emphasis on mental health, neurological imbalances, and women's health, where Phase II success rates (e.g., 54% PTSR for vasomotor symptoms drugs like NOE-115) signal viable paths to approval amid regulatory support for rare diseases.[3] Market forces favoring Noema include biotech investor interest in de-risked, in-licensed assets from big pharma like Roche, plus a pipeline spanning orphan (trigeminal neuralgia, Tourette) to larger populations (menopause), broadening impact.[2][4] It influences the ecosystem by accelerating CNS innovation through patient partnerships and clinical readouts, potentially setting benchmarks for network-modulating therapies in underserved areas.[5][6]
Noema's near-term catalysts include ongoing Phase 2b/3 readouts for NOE-105 in Tourette syndrome and NOE-101 in trigeminal neuralgia, alongside NOE-115 advancement in menopause symptoms, with potential Phase III transitions bolstered by recent financing and executive hires.[3][4] Trends like AI-driven drug discovery, precision neurology, and expanded CNS indications will shape its path, amplifying growth if endpoints hold. Influence may evolve from niche orphan player to broader CNS leader, delivering transformative therapies that enable fuller lives for patients with brain disorders—aligning with its mission to pioneer beyond symptom control.[2][6]
Noema Pharma has raised $260.0M across 2 funding rounds. Most recently, it raised $150.0M Series B in December 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2024 | $150.0M Series B | EQT Life Sciences, Forbion, Karista, Pfizer Venture Investments, Seroba Life Sciences, Soffinova Partners | |
| Mar 1, 2023 | $110.0M Series B | Forbion, Karista, Pfizer Venture Investments, Seroba Life Sciences, Soffinova Partners |